Researchers at Peel Hunt Kept the Same their “Add” rating for Lancashire Holdings Ltd (LON:LRE). The Price Objective is Set to GBX 645.00; Shorts at Sonoma Pharmaceuticals (SNOA) Raised By 76.28%

Lancashire Holdings Limited (LON:LRE) Logo

In a report issued on Friday morning, Lancashire Holdings Ltd (LON:LRE) stock had its “Add” Rating maintained by equity analysts at Peel Hunt. They currently have a GBX 645.00 price target on firm. Peel Hunt’s target would indicate a potential upside of 9.14% from the company’s last stock price.

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) had an increase of 76.28% in short interest. SNOA’s SI was 509,800 shares in January as released by FINRA. Its up 76.28% from 289,200 shares previously. With 587,600 avg volume, 1 days are for Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s short sellers to cover SNOA’s short positions. The stock increased 2.05% or $0.0144 during the last trading session, reaching $0.717. About 16,226 shares traded. Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) has declined 83.30% since January 11, 2018 and is downtrending. It has underperformed by 83.30% the S&P500. Some Historical SNOA News: 27/03/2018 Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution; 17/04/2018 – Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products; 08/05/2018 – Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer; 05/04/2018 – Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel; 17/04/2018 – SONOMA PHARMACEUTICALS – 4 APPROVALS ENCOMPASS HYPOCHLOROUS ACID-BASED PRODUCTS FOR TREATMENT OF ACNE AS WELL AS ANTI-FUNGAL INDICATIONS

More news for Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) were recently published by: Globenewswire.com, which released: “Sonoma Pharmaceuticals Introduces New and Improved Acuicynâ„¢ Antimicrobial Eyelid and Eyelash Hygiene Solution – GlobeNewswire” on March 27, 2018. Seekingalpha.com‘s article titled: “Sonoma Pharmaceuticals: Insider Buying And Growing Sales Make This A Buy – Seeking Alpha” and published on December 06, 2017 is yet another important article.

Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company has market cap of $4.73 million. The firm offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains. It currently has negative earnings. The Company’s products also include Celacyn, a prescription hypochlorous acid based scar management gel; Ceramax Skin Barrier Cream to manage dry itchy skin, minor skin irritations, rashes, and inflammation; Mondoxyne, a prescription oral tetracycline antibiotic for the treatment of various bacterial infections; Alevicyn, a prescription hypochlorous acid based atopic dermatitis product line to reduce itch and pain associated with various dermatoses; and SebuDerm, a prescription topical gel for the management of burning, itching, and scaling in seborrhea and seborrheic dermatitis.

Lancashire Holdings Limited provides specialty insurance and reinsurance products worldwide. The company has market cap of 1.18 billion GBP. The firm operates through five divisions: Property, Energy, Marine, Aviation, and Lloyd??s. It has a 25.7 P/E ratio. It offers aviation insurance solutions; coverage for upstream operational and construction all risks related to wind, earthquakes, and floods, as well as standalone business interruption coverage; and a range of coverages in marine portfolio, including marine hull, total loss only, mortgagees interests insurance, mortgagees additional perils, excess protection and indemnity, marine war, and builder??s risks to high-profile accounts, cruise vessels, and liquid natural gas carriers.

The stock decreased 1.42% or GBX 8.5 during the last trading session, reaching GBX 591. About 47,736 shares traded. Lancashire Holdings Limited (LON:LRE) has 0.00% since January 11, 2018 and is . It has by 0.00% the S&P500.

Another recent and important Lancashire Holdings Limited (LON:LRE) news was published by Nasdaq.com which published an article titled: “This Insurance Company Is Almost Unbelievably Profitable – Nasdaq” on October 23, 2017.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.